Sign in or create an account to add this stock to your watchlist.
About Viewray (NASDAQ:VRAY)
ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company's software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VRAY
CUSIPN/A
Phone440-703-3210
Debt
Debt-to-Equity Ratio0.77
Current Ratio3.79
Quick Ratio3.04
Price-To-Earnings
Trailing P/E Ratio-6.72
Forward P/E Ratio-10.75
P/E GrowthN/A
Sales & Book Value
Annual Sales$34.04 million
Price / Sales14.73
Cash FlowN/A
Price / CashN/A
Book Value$0.80 per share
Price / Book8.74
Profitability
EPS (Most Recent Fiscal Year)($1.04)
Net Income$-72,170,000.00
Net Margins-83.09%
Return on Equity-1,375.57%
Return on Assets-44.36%
Miscellaneous
Employees139
Outstanding Shares71,740,000
Viewray (NASDAQ:VRAY) Frequently Asked Questions
What is Viewray's stock symbol?
Viewray trades on the NASDAQ under the ticker symbol "VRAY."
How were Viewray's earnings last quarter?
Viewray Inc (NASDAQ:VRAY) released its quarterly earnings results on Thursday, May, 10th. The company reported ($0.11) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.20) by $0.09. The business earned $26.19 million during the quarter, compared to analysts' expectations of $15.50 million. Viewray had a negative return on equity of 1,375.57% and a negative net margin of 83.09%. The company's quarterly revenue was up 2029.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.54) earnings per share. View Viewray's Earnings History.
What price target have analysts set for VRAY?
5 brokers have issued 1 year price targets for Viewray's stock. Their predictions range from $10.00 to $13.50. On average, they anticipate Viewray's stock price to reach $11.90 in the next year. View Analyst Ratings for Viewray.
What are Wall Street analysts saying about Viewray stock?
Here are some recent quotes from research analysts about Viewray stock:
- 1. Cantor Fitzgerald analysts commented, "Strong 1Q results. VRAY reported $26.2MM of revenue in 1Q, beating Street expectations by $13.1MM. Revenue was higher than expected due to delayed revenue recognition of a system installed in 4Q, earlier-than-expected recognition from an installation in late-1Q, and a system upgrade from the previous generation MRIdian Cobalt. VRAY placed four systems and upgraded one, which was in line with our expectations. VRAY received gross orders of $21MM, slightly below our expectation of $24MM. The backlog at the end of the quarter was $195MM, down slightly from $204MM last quarter." (5/11/2018)
- 2. Mizuho analysts commented, "We were at the Advanced Applications of MR-Guided Radiotherapy Symposium in Amsterdam on March 16th, 2018. The event was very well attended with approximately 200 people; most were potential customers who showed strong interest in ViewRay’s MRIdian. We highlight our key takeaways from the conference and additional insights into the MRI Linac below. Overall, we maintain our view that ViewRay has leadership in real time imaging guided LINAC today." (4/19/2018)
Who are some of Viewray's key competitors?
Some companies that are related to Viewray include CONMED (CNMD), NxStage Medical (NXTM), AxoGen (AXGN), Natus Medical (BABY), Cutera (CUTR), Rockwell Medical (RMTI), Vision Sciences (CGNT), Helius Medical Technologies (HSDT), Fonar (FONR), Second Sight Medical Products (EYES), Biolife Solutions (BLFS), Zynex (ZYXI), IRIDEX (IRIX), Semler Scientific (SMLR) and Edap Tms (EDAP).
When did Viewray IPO?
(VRAY) raised $52 million in an initial public offering on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and BTIG and Brean Capital were co-managers.
Has Viewray been receiving favorable news coverage?
Headlines about VRAY stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Viewray earned a daily sentiment score of 0.18 on Accern's scale. They also gave media coverage about the company an impact score of 47.20 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are Viewray's major shareholders?
Viewray's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Fosun International Ltd (15.01%), Park West Asset Management LLC (4.80%), BlackRock Inc. (2.59%), Acuta Capital Partners LLC (2.58%), Next Century Growth Investors LLC (0.80%) and Russell Investments Group Ltd. (0.57%). Company insiders that own Viewray stock include Aditya Puri, Ajay Bansal, David P Bonita, Fmr Llc, Henry A Mckinnell and James F Dempsey. View Institutional Ownership Trends for Viewray.
Which institutional investors are selling Viewray stock?
VRAY stock was sold by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, Next Century Growth Investors LLC, Alpine Woods Capital Investors LLC and A.R.T. Advisors LLC. View Insider Buying and Selling for Viewray.
Which institutional investors are buying Viewray stock?
VRAY stock was acquired by a variety of institutional investors in the last quarter, including Fosun International Ltd, Park West Asset Management LLC, Millennium Management LLC, Thompson Siegel & Walmsley LLC, UBS Group AG, Russell Investments Group Ltd., Barclays PLC and Schwab Charles Investment Management Inc.. Company insiders that have bought Viewray stock in the last two years include Aditya Puri, Ajay Bansal, David P Bonita and Henry A Mckinnell. View Insider Buying and Selling for Viewray.
How do I buy shares of Viewray?
Shares of VRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Viewray's stock price today?
One share of VRAY stock can currently be purchased for approximately $6.99.
How big of a company is Viewray?
Viewray has a market capitalization of $506.51 million and generates $34.04 million in revenue each year. The company earns $-72,170,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis. Viewray employs 139 workers across the globe.
How can I contact Viewray?
Viewray's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company can be reached via phone at 440-703-3210 or via email at [email protected]
MarketBeat Community Rating for Viewray (VRAY)
MarketBeat's community ratings are surveys of what our community members think about Viewray and other stocks. Vote "Outperform" if you believe VRAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
Viewray (NASDAQ:VRAY) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for Viewray in the last 12 months. Their average twelve-month price target is $11.90, suggesting that the stock has a possible upside of 70.24%. The high price target for VRAY is $13.50 and the low price target for VRAY is $10.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $11.90 | $11.5833 | $11.5833 | $10.60 |
| Price Target Upside: | 70.24% upside | 50.43% upside | 41.61% upside | 12.41% upside |
Viewray (NASDAQ:VRAY) Consensus Price Target History
Viewray (NASDAQ:VRAY) Analyst Ratings History
Show:
(Data available from 5/25/2016 forward)
Viewray (NASDAQ:VRAY) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Viewray (NASDAQ VRAY) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 62.81%
Institutional Ownership Percentage: 83.35%
Viewray (NASDAQ VRAY) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/14/2018 | James F Dempsey | Insider | Sell | 75,243 | $7.57 | $569,589.51 | |  |
| 4/25/2017 | Fmr Llc | Insider | Sell | 106,781 | $6.76 | $721,839.56 | | |
| 4/24/2017 | Fmr Llc | Insider | Sell | 101,139 | $6.71 | $678,642.69 | | |
| 4/20/2017 | Fmr Llc | Insider | Sell | 101,236 | $6.90 | $698,528.40 | | |
| 4/18/2017 | Fmr Llc | Insider | Sell | 107,217 | $7.24 | $776,251.08 | | |
| 4/13/2017 | Fmr Llc | Insider | Sell | 115,860 | $7.44 | $861,998.40 | | |
| 4/12/2017 | Fmr Llc | Insider | Sell | 179,494 | $7.40 | $1,328,255.60 | | |
| 4/10/2017 | Fmr Llc | Insider | Sell | 178,556 | $7.77 | $1,387,380.12 | | |
| 4/7/2017 | Fmr Llc | Insider | Sell | 52,050 | $7.89 | $410,674.50 | | |
| 4/5/2017 | Fmr Llc | Insider | Sell | 196,397 | $7.90 | $1,551,536.30 | | |
| 4/3/2017 | Fmr Llc | Insider | Sell | 217,883 | $8.29 | $1,806,250.07 | | |
| 3/30/2017 | Fmr Llc | Insider | Sell | 28,661 | $8.46 | $242,472.06 | | |
| 1/18/2017 | Ajay Bansal | CFO | Buy | 62,597 | $3.17 | $198,432.49 | 70,104 | |
| 1/18/2017 | Henry A. Mckinnell | Director | Buy | 312,989 | $3.17 | $992,175.13 | | |
| 9/9/2016 | Aditya Puri | Director | Buy | 1,472,803 | $2.95 | $4,344,768.85 | 18,964 | |
| 8/22/2016 | David P Bonita | Director | Buy | 1,138,074 | $2.95 | $3,357,318.30 | | |
(Data available from 1/1/2013 forward)
Viewray (NASDAQ VRAY) News Headlines
| Source: |
|
Viewray (NASDAQ:VRAY) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Viewray (NASDAQ VRAY) Stock Chart for Friday, May, 25, 2018
Loading chart…
